



Thursday, July 9, 2015
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Tony Dalpiaz, PharmD.
Michael Symond, M.D.
Keith Tolman, M.D.
Mark Balk, PharmD.

Jennifer Brinton, MD
Jay Aldus, DDS
George Hamblin, PharmD
Mr. Kumar Shah

Board Members Excused:

Susan Siegfroid, M.D

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, Pharm.D
Trevor Smith C.Ph.T.
Heather Santacruz, R.N .

Chad Hope, Pharm.D.
Merelynn Berrett, R.N.
Alyssa Pitts, R.N.

Other Individuals Present:

Joanita Lake, UofU
Gary Oderda, UofU
Lovell Robinson, Abbvie
Sushma Patel, AstraZeneca

Natasha Ruiz, UofU
Charissa Anne, J&J
Michelle Bice, Gilead

Meeting conducted by: Tony Dalpiaz, Pharm.D.

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She also welcomed Chad Hope, the new Utah Medicaid pharmacy director.
- 3. P&T Committee report** – Robyn Seely reported that Lisa Hunt has resigned from Utah Medicaid. She will work on the Wyoming board of pharmacy. The next P&T meeting will discuss agents to treat angina and hepatitis C combination agents.
- 4. Approval of prior meeting minutes** – Keith Tolman made a motion to approve the May meeting minutes. Kumar Shah seconded the motion. All in favor.
- 5. Synagis – 9 month review** – Robyn Seely said that the PA set last year on Synagis is working well and sees no problem with keeping the same criteria for this next year.

6. Androgens (Aveed, Natesto, Vogelxo) – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about the three androgen products. Data was also presented about the utilization of the drugs in the Utah Medicaid population.

7. Public Comment

- a. No Public Comment.

8. Board Discussion

- a. Robyn Seely presented the current PA criteria for androgen products.
- b. Keith Tolman asked about the process for children to receive the medication. Robyn said that all requests for children are reviewed and if it is prescribed for a valid diagnosis, a PA is approved. She said these cases are rare.
- c. Mark Balk asked about why the current PA criteria lists age 19, instead of 18. He recommended that the board change it to the recommended age 18.
- d. Chad Hope said that the diagnosis codes will need to be changed from ICD-9 to ICD-10 with the required change in October 2015.
- e. Mike Symond recommended that the criteria be changed to only require one lab value while on treatment instead of two.
- f. Keith Tolman said that, while off label, these drugs are good for treating liver disease and Hodgkins disease for symptoms of pruritus.
- g. Mike Symond made a motion to change the age on the criteria sheet for males to 18 from 19, change required labs to 1 from 2, update the ICD-9 informatin to ICD-10. He also made a motion that the androgen criteria for females should require a diagnosis code. Mark Balk seconded the motion. All in favor.

9. Meeting Adjourned – Mark Balk made a motion to close the meeting. Tony Dalpiaz seconded the motion. All in favor.

The next DUR Board meeting is scheduled for Thursday, August 13th. Tentative schedule is to discuss hyaluronic acid derivatives.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov